论文部分内容阅读
慢性肾脏疾病和血脂异常常同时出现,两者均可增加心血管事件的发生率。调脂治疗对降低慢性肾脏疾病病人心血管事件发生率有利,慢性肾脏疾病病人调脂治疗的安全性值得重视。本文对不同阶段的慢性肾脏疾病病人在各种血脂异常时的调脂治疗策略作一综述。他汀类药物中以阿托伐他汀和氟伐他汀较为安全。
Chronic kidney disease and dyslipidemia often occur simultaneously, both of which can increase the incidence of cardiovascular events. Lipid-lowering therapy is beneficial to reduce the incidence of cardiovascular events in patients with chronic kidney disease, and the safety of lipid-lowering therapy in patients with chronic kidney disease deserves attention. This article reviews the different stages of chronic kidney disease patients in a variety of dyslipidemia lipid-lowering treatment strategies are reviewed. Statins are safer with atorvastatin and fluvastatin.